Cargando…

A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study

Chronic obstructive pulmonary disease (COPD) is an inflammatory lung condition, causing progressive decline in lung function leading to premature death. Acute exacerbations in COPD patients are predominantly associated with respiratory viruses. Ribavirin is a generic broad-spectrum antiviral agent t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumont, Etienne F., Oliver, Amanda J., Ioannou, Chris, Billiard, Julia, Dennison, Jeremy, van den Berg, Frans, Yang, Shuying, Chandrasekaran, Vijayalakshmi, Young, Graeme C., Lahiry, Anirban, Starbuck, David C., Harrell, Andrew W., Georgiou, Alex, Hopchet, Nathalie, Gillies, Andy, Baker, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179635/
https://www.ncbi.nlm.nih.gov/pubmed/32071044
http://dx.doi.org/10.1128/AAC.02267-19
_version_ 1783525679160098816
author Dumont, Etienne F.
Oliver, Amanda J.
Ioannou, Chris
Billiard, Julia
Dennison, Jeremy
van den Berg, Frans
Yang, Shuying
Chandrasekaran, Vijayalakshmi
Young, Graeme C.
Lahiry, Anirban
Starbuck, David C.
Harrell, Andrew W.
Georgiou, Alex
Hopchet, Nathalie
Gillies, Andy
Baker, Stephen J.
author_facet Dumont, Etienne F.
Oliver, Amanda J.
Ioannou, Chris
Billiard, Julia
Dennison, Jeremy
van den Berg, Frans
Yang, Shuying
Chandrasekaran, Vijayalakshmi
Young, Graeme C.
Lahiry, Anirban
Starbuck, David C.
Harrell, Andrew W.
Georgiou, Alex
Hopchet, Nathalie
Gillies, Andy
Baker, Stephen J.
author_sort Dumont, Etienne F.
collection PubMed
description Chronic obstructive pulmonary disease (COPD) is an inflammatory lung condition, causing progressive decline in lung function leading to premature death. Acute exacerbations in COPD patients are predominantly associated with respiratory viruses. Ribavirin is a generic broad-spectrum antiviral agent that could be used for treatment of viral respiratory infections in COPD. Using the Particle Replication In Nonwetting Templates (PRINT) technology, which produces dry-powder particles of uniform shape and size, two new inhaled formulations of ribavirin (ribavirin-PRINT-CFI and ribavirin-PRINT-IP) were developed for efficient delivery to the lung and to minimize bystander exposure. Ribavirin-PRINT-CFI was well tolerated in healthy participants after single dosing and ribavirin-PRINT-IP was well tolerated in healthy and COPD participants after single and repeat dosing. Ribavirin-PRINT-CFI was replaced with ribavirin-PRINT-IP since the latter formulation was found to have improved physicochemical properties and it had a higher ratio of active drug to excipient per unit dose. Ribavirin concentrations were measured in lung epithelial lining fluid in both healthy and COPD participants and achieved target concentrations. Both formulations were rapidly absorbed with approximately dose proportional pharmacokinetics in plasma. Exposure to bystanders was negligible based on both the plasma and airborne ribavirin concentrations with the ribavirin-PRINT-IP formulation. Thus, ribavirin-PRINT-IP allowed for an efficient and convenient delivery of ribavirin to the lungs while minimizing systemic exposure. Further clinical investigations would be required to demonstrate ribavirin-PRINT-IP antiviral characteristics and impact on COPD viral-induced exacerbations. (The clinical trials discussed in this study have been registered at ClinicalTrials.gov under identifiers NCT03243760 and NCT03235726.)
format Online
Article
Text
id pubmed-7179635
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-71796352020-04-27 A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study Dumont, Etienne F. Oliver, Amanda J. Ioannou, Chris Billiard, Julia Dennison, Jeremy van den Berg, Frans Yang, Shuying Chandrasekaran, Vijayalakshmi Young, Graeme C. Lahiry, Anirban Starbuck, David C. Harrell, Andrew W. Georgiou, Alex Hopchet, Nathalie Gillies, Andy Baker, Stephen J. Antimicrob Agents Chemother Antiviral Agents Chronic obstructive pulmonary disease (COPD) is an inflammatory lung condition, causing progressive decline in lung function leading to premature death. Acute exacerbations in COPD patients are predominantly associated with respiratory viruses. Ribavirin is a generic broad-spectrum antiviral agent that could be used for treatment of viral respiratory infections in COPD. Using the Particle Replication In Nonwetting Templates (PRINT) technology, which produces dry-powder particles of uniform shape and size, two new inhaled formulations of ribavirin (ribavirin-PRINT-CFI and ribavirin-PRINT-IP) were developed for efficient delivery to the lung and to minimize bystander exposure. Ribavirin-PRINT-CFI was well tolerated in healthy participants after single dosing and ribavirin-PRINT-IP was well tolerated in healthy and COPD participants after single and repeat dosing. Ribavirin-PRINT-CFI was replaced with ribavirin-PRINT-IP since the latter formulation was found to have improved physicochemical properties and it had a higher ratio of active drug to excipient per unit dose. Ribavirin concentrations were measured in lung epithelial lining fluid in both healthy and COPD participants and achieved target concentrations. Both formulations were rapidly absorbed with approximately dose proportional pharmacokinetics in plasma. Exposure to bystanders was negligible based on both the plasma and airborne ribavirin concentrations with the ribavirin-PRINT-IP formulation. Thus, ribavirin-PRINT-IP allowed for an efficient and convenient delivery of ribavirin to the lungs while minimizing systemic exposure. Further clinical investigations would be required to demonstrate ribavirin-PRINT-IP antiviral characteristics and impact on COPD viral-induced exacerbations. (The clinical trials discussed in this study have been registered at ClinicalTrials.gov under identifiers NCT03243760 and NCT03235726.) American Society for Microbiology 2020-04-21 /pmc/articles/PMC7179635/ /pubmed/32071044 http://dx.doi.org/10.1128/AAC.02267-19 Text en Copyright © 2020 Dumont et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Antiviral Agents
Dumont, Etienne F.
Oliver, Amanda J.
Ioannou, Chris
Billiard, Julia
Dennison, Jeremy
van den Berg, Frans
Yang, Shuying
Chandrasekaran, Vijayalakshmi
Young, Graeme C.
Lahiry, Anirban
Starbuck, David C.
Harrell, Andrew W.
Georgiou, Alex
Hopchet, Nathalie
Gillies, Andy
Baker, Stephen J.
A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study
title A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study
title_full A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study
title_fullStr A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study
title_full_unstemmed A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study
title_short A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study
title_sort novel inhaled dry-powder formulation of ribavirin allows for efficient lung delivery in healthy participants and those with chronic obstructive pulmonary disease in a phase 1 study
topic Antiviral Agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179635/
https://www.ncbi.nlm.nih.gov/pubmed/32071044
http://dx.doi.org/10.1128/AAC.02267-19
work_keys_str_mv AT dumontetiennef anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT oliveramandaj anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT ioannouchris anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT billiardjulia anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT dennisonjeremy anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT vandenbergfrans anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT yangshuying anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT chandrasekaranvijayalakshmi anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT younggraemec anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT lahiryanirban anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT starbuckdavidc anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT harrellandreww anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT georgioualex anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT hopchetnathalie anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT gilliesandy anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT bakerstephenj anovelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT dumontetiennef novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT oliveramandaj novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT ioannouchris novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT billiardjulia novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT dennisonjeremy novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT vandenbergfrans novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT yangshuying novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT chandrasekaranvijayalakshmi novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT younggraemec novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT lahiryanirban novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT starbuckdavidc novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT harrellandreww novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT georgioualex novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT hopchetnathalie novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT gilliesandy novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study
AT bakerstephenj novelinhaleddrypowderformulationofribavirinallowsforefficientlungdeliveryinhealthyparticipantsandthosewithchronicobstructivepulmonarydiseaseinaphase1study